Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Cemiplimab for Stage II–IV (M0) Cutaneous Squamous Cell Carcinoma
2022-500811-37-00Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Pathologic complete response rate. Started Jan 2021; status: completed.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2022-500811-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500811-37-00.